Clinical Trials on NMIBC

Total 22 results

RemeGen Co., Ltd.

Recruiting

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

NMIBC

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-1501 Alone or in Combination With BCG in Subjects With NMIBC

High-risk NMIBC

China
Prokarium Ltd

Recruiting

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer (PARADIGM-1)

NMIBC | Non Muscle Invasive Bladder Cancer | High Risk NMIBC

United States
Anchiano Therapeutics Israel Ltd.

Terminated

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Non-muscle Invasive Bladder Cancer (NMIBC)

United States
Asieris Pharmaceutical Technologies Co., Ltd.

Completed

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment (NMIBC)

Non-Muscle Invasive Bladder Cancer (NMIBC)

United States
Case Comprehensive Cancer Center

Withdrawn

Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors

Non-muscle Invasive Bladder Cancer (NMIBC) | Bladder Tumor (TURBT)

United States
Aadi Bioscience, Inc.
National Cancer Institute (NCI)

Completed

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer (NMIBC)

United States
University of Oxford
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (PemBla)

Non-muscle Invasive Bladder Cancer (NMIBC)

United Kingdom
Theralase® Technologies Inc.
University Health Network, Toronto; Pharma eMarket

Recruiting

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

United States, Canada
Theralase Inc.
University Health Network, Toronto; WCCT Global; Medelis Inc.

Completed

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG

Canada
Mansoura University

Unknown

Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?

Non-Muscle-invasive Bladder Cancer (NMIBC) | Bacillus Calmette-Guerin (BCG) Cystitis | Intra-vesical Instillation

Egypt
Mansoura University

Unknown

Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology Resident

Pain, Postoperative | Bladder Cancer | Flexible Cystoscopy | Non-muscle Invasive Bladder Cancer (NMIBC)

Egypt
UNICANCER

Recruiting

Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30) (Bladder-ART)

Patients With High-risk MIBC

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Incyte Corporation

Recruiting

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Bladder Cancer | NMIBC | Urothelial Carcinoma Recurrent | Non-Muscle Invasive Bladder Cancer

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC

Non-Muscle-Invasive Bladder Cancer (NMIBC)

China
Ractigen Therapeutics.

Recruiting

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Australia
Memorial Sloan Kettering Cancer Center

Recruiting

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Non-Muscle Invasive Bladder Cancer (NMIBC)

United States
Mayo Clinic

Recruiting

Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)

Non-muscle Invasive Bladder Cancer | Stage 0a Bladder Cancer AJCC v8 | NMIBC

United States
Vitadx
FONDATION FORCE POUR L'INNOVATION ET LA RECHERCHE EN SANTE

Recruiting

Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test (DMIA)

Non-muscle Invasive Bladder Cancer (NMIBC)

France, Belgium, Spain
Astellas Pharma Global Development, Inc.
Seagen Inc.

Recruiting

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Carcinoma in Situ | Urinary Bladder Neoplasms | Non-muscle Invasive Bladder Cancer | Carcinoma Transitional Cell | NMIBC

United States, Canada, France, Spain, United Kingdom
Fidia Farmaceutici s.p.a.

Terminated

Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.

Non-muscle Invasive Bladder Cancer (NMIBC)

Italy
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain

Clinical Trials on NMIBC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations